NASDAQ: SYRE - Spyre Therapeutics, Inc.

Yield per half year: -3.25%
Sector: Healthcare

Share chart Spyre Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Spyre Therapeutics, Inc., биотехнологическая компания, специализируется на продвижении линейки терапевтических средств на основе антител для лечения воспалительных заболеваний кишечника путем объединения инженерии антител, рациональных терапевтических комбинаций и прецизионных медицинских подходов к отбору пациентов. В портфолио компании входят антитела с увеличенным периодом полураспада, нацеленные на a4β7, TL1A и IL-23. Компания ранее была известна как Aeglea BioTherapeutics, Inc. и сменила название на Spyre Therapeutics, Inc. в ноябре 2023 года. Spyre Therapeutics, Inc.

More details
была основана в 2013 году и базируется в Уолтеме, штат Массачусетс.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 35.99
ISIN US00773J2024
Выручка 0.0187
P/S 16.67
P/BV 4.09
Сайт https://www.spyre.com
Число акций ао 0.0069 млрд
EBITDA -0.0794
EV/EBITDA -2.92
Валюта usd
IPO date 2016-04-07
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +5.39% (34.15)
Change price per week: +26.86% (28.37)
Change price per month: +24.19% (28.98)
Change price per 3 month: +21.26% (29.68)
Change price per half year: -3.25% (37.2)
Change price per year: +203.46% (11.86)
Change price per 3 year: +371.69% (7.63)
Change price per 5 year: +376.69% (7.55)
Change price per year to date: +260.98% (9.97)
All parameters

Underestimation

Title Value Grade
P/S 141.44 1
P/BV 0.681 10
P/E 0 0
EV/EBITDA 0.3021 10
Total: 5.88

Efficiency

Title Value Grade
ROA, % -99.1 0
ROE, % -184.11 0
Total: 3.17

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 1.22 8
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -82.98 0
Yield Ebitda, % -187.47 0
Yield EPS, % -31.33 0
Total: 2.8
More

Institutions Volume Share, %
Driehaus Capital Management, LLC 800853 19.78
Franklin Resources, Inc. 687090 16.97
Fairmount Funds Management LLC 378421 9.35
Polar Capital Holdings PLC 300000 7.41
Wellington Management Group, LLP 299929 7.41
VR Adviser, LLC 295034 7.29
Affinity Asset Advisors, LLC 242297 5.98
Logos Global Management LP 210000 5.19
EcoR1 Capital, LLC 199996 4.94
Suvretta Capital Management, LLC 162395 4.01

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Morningstar Small-Cap ETF 0.02198 37.681332167863 1.60498
iShares Morningstar Small-Cap Growth ETF 0.02 41.553945249597 0.72598
iShares Morningstar Small Cap Value ETF 0.02406 40.493824576094 2.50476
iShares Russell 2000 Growth ETF 0.00646 47.42032299557 0.6026
iShares Russell 3000 ETF 0.00187 37.942616648456 1.43482
iShares Morningstar Small-Cap ETF 0.02198 410.50632631881 1.60498
iShares Morningstar Small-Cap Growth ETF 0.02 757.51743375174 0.72598
iShares Morningstar Small-Cap Value ETF 0.02406 252.86210418795 2.50476



Head Job title Payment Year of birth
Dr. Cameron Turtle DPHIL, Ph.D. CEO & Director 674.17k 1990 (34 years)
Mr. Scott L. Burrows Chief Financial Officer 331.81k 1977 (47 years)
Dr. Janet Gunzner-Toste M.B.A., Ph.D. Senior Vice President of Operations N/A
Mr. Eric McIntyre Vice President of Finance & Investor Relations N/A
Ms. Heidy Abreu King-Jones J.D., L.L.M. Chief Legal Officer & Corporate Secretary 568.87k 1983 (41 year)
Mr. James Myers Vice President of Quality & Compliance N/A
Dr. Kelly Boothe Ph.D. Senior Director of Corporate Communications & Investor Relations N/A
Dr. Justin LaFountaine Ph.D. Senior Vice President of Corporate Development N/A
Mr. Brian Connolly Chief Technical Officer N/A
Ms. Melissa Cooper Senior Vice President of People N/A

Address: United States, Waltham. MA, 221 Crescent Street - open in Google maps, open in Yandex maps
Website: https://www.spyre.com